A Clinical Study of 6MW3211 in Patients With Renal Cancer
NCT ID: NCT05440045
Last Updated: 2022-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2022-09-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
NCT06222125
A Phase II Study of AS1411 in Renal Cell Carcinoma
NCT00740441
Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.
NCT06574412
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
NCT00005045
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
NCT02118337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
6MW3211
6MW3211 injection, 30mg/kg
6MW3211
6MW3211 injection, 30mg/kg, Q2W
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
6MW3211
6MW3211 injection, 30mg/kg, Q2W
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Advanced clear cell renal cancer.
* At least one measurable tumor target lesion.
* Life expectancy≥3 months.
* Suitable organ functions.
* Patients who had failed at least one line therapy.
* ECOG 0-1.
* The samples of tumor tissue should be provided
Exclusion Criteria
* History of other malignant tumors within 5 years.
* Patients with CNS metastasis.
* History of active autoimmune diseases.
* Patients with poor-controlled systemic diseases after treatment.
* Patients with severe infection or requiring antibiotic treatment within 4 weeks before dosing.
* Adverse reactions related to previous treatments failed to recover to CTCAE 5.0 ≤1
* Patients who had experienced immune-related adverse events (irAE) with grade 3 or above.
* Patients who were allergic to any composition of experimental drug.
* Subjects with poor treatment compliance.
* Pregnant or lactating woman.
* Live vaccination within 28 days before first dosing.
* History of drug abuse or addiction
* Patients with active HBV or HCV, or HIV antibody positive,or Tp-Ab positive.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mabwell (Shanghai) Bioscience Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6MW3211-2022-CP202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.